Article may be outdated

This article is 4 days old. Some details may have changed since publication.

Times of India·3 min read·medium

Breakthrough HIV drug sees 18 patent filings, may delay affordable generics

R
RUPALI MUKHERJEE
Breakthrough HIV drug sees 18 patent filings, may delay affordable generics
✦AI Summary

Gilead Sciences has filed 18 patent applications in India for its HIV drug lenacapavir, sparking concerns over 'evergreening' practices. Patient groups argue these filings are intended to delay generic competition and maintain high prices.

Why it matters

This case represents a significant conflict between pharmaceutical intellectual property rights and global access to essential, life-saving medicines.

✦Dive DeeperCreate a free account to unlock

NEW DELHI: An unusually high 18 patent applications filed in India for lenacapavir, a breakthrough HIV therapy, have raised concerns that these could prolong market exclusivity, delay affordable generics, keep prices high and restrict patient access. Contesting the move, patient groups and civil society have filed opposition with the regulatory authorities, arguing the applications lack novelty and inventive steps.Lenacapavir, a long-acting injectable, administered twice yearly for both HIV prevention and treatment, a medicine designated as essential by WHO.Last year, US FDA approved Gilead Sciences' lenacapavir as the first and only twice-yearly injectable pre-exposure prophylaxis to reduce sexually acquired HIV.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthbusinessscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in